Related Experiment Videos
Mutational resistance to 4-quinolone antibacterial agents
European Journal of Clinical Microbiology
|August 1, 1984
Summary
Ten 4-quinolone drugs showed reduced activity against Escherichia coli mutants due to cross-resistance. However, highly active drugs like ciprofloxacin remain effective within human serum levels, suggesting clinical cross-resistance may not always apply.
Area of Science:
- Microbiology
- Pharmacology
- Drug Resistance
Background:
- 4-quinolone drugs are a class of antibacterial agents.
- Escherichia coli is a common bacterium that can develop resistance to antibiotics.
- Understanding drug resistance mechanisms is crucial for effective treatment.
Purpose of the Study:
- To evaluate the activity of ten 4-quinolone drugs against Escherichia coli mutants.
- To investigate the phenomenon of biochemical cross-resistance among these drugs.
- To determine if clinical cross-resistance is a significant issue for highly active 4-quinolones.
Main Methods:
- Testing the activity of ten different 4-quinolone antibacterial agents.
- Utilizing five distinct mutants of Escherichia coli.
- Assessing drug activity in relation to bacterial resistance levels.
Main Results:
- Mutational resistance reduced the activity of all ten tested 4-quinolone drugs.
- Biochemical cross-resistance was observed among the drugs.
- Ciprofloxacin, ofloxacin, and norfloxacin demonstrated high activity, with resistance levels below human serum concentrations.
Conclusions:
- While mutational resistance impacts 4-quinolone activity, high-potency agents like ciprofloxacin may overcome this.
- Clinical cross-resistance in Escherichia coli might not be a limiting factor for certain highly active 4-quinolones.
- Further research is needed to fully understand the clinical implications of 4-quinolone resistance.